Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Abstract

Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an increase in AR protein degradation. These open-label phase I and II studies [Androgen Receptor Modulation Optimized for Response-1 (ARMOR1) and ARMOR2 part 1] evaluated the efficacy and safety of galeterone in patients with treatment-naive nonmetastatic or metastatic castration-resistant prostate cancer (CRPC) and established a dose for further study.Experimental Design: In ARMOR1, 49 patients received increasing doses (650-2,600 mg) of galeterone in capsule formulation; 28 patients in ARMOR2 part 1 received increasing doses (1,700-3,400 mg) of galeterone in tablet formulation for 12 weeks. Patients were evaluated biweekly for safety and efficacy, and pharmacokinetic parameters were assessed.Results: In ARMOR1, across all doses, 49.0% (24/49) achieved a !30% decline in prostate-specific antigen (PSA; PSA30) and 22.4% (11/49) demonstrated a !50% PSA decline (PSA50). In ARMOR2 part 1, across all doses, PSA30 was 64.0% (16/25) and PSA50 was 48.0% (12/25). In the 2,550-mg dose cohort, PSA30 was 72.7% (8/11) and PSA50 was 54.5% (6/11). Galeterone was well tolerated; the most common adverse events were fatigue, increased liver enzymes, gastrointestinal events, and pruritus. Most were mild or moderate in severity and required no action and there were no apparent mineralocorticoid excess (AME) events.Conclusions: The efficacy and safety from ARMOR1 and ARMOR2 part 1 and the pharmacokinetic results support the galeterone tablet dose of 2,550 mg/d for further study. Galeterone was well tolerated and demonstrated pharmacodynamic changes consistent with its selective, multifunctional AR signaling inhibition.

MAPK pathway mediates the anti‑oxidative effect of chicoric acid against cerebral ischemia‑reperfusion injury in�vivo

“…Cerebrovascular disease has high morbidity, death rates and disability rates worldwide, posing a serious threat to public health (14). Approximately 2 million individuals suffer from cerebrovascular disease worldwide and >1.5 million succumb each year (14).…”

“…Approximately 2 million individuals suffer from cerebrovascular disease worldwide and >1.5 million succumb each year (14). Furthermore, the morbidity is on the increase with improvements in living standards and lifestyle changes (1).…”

“…Rats were injected with 35 mg/kg pentobarbital sodium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). A cerebral I/R rat model was induced by transient middle cerebral artery occlusion (MCAO) for 1 h as described previously (14). In the negative control group, surgery was performed in the same way without inserting threads.…”

The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition

“…In a phase I study of chemonaive men with CRPC, 22% demonstrated a decrease in PSA of more than 50%, whereas an additional 26% had a PSA decline of 30-50% after 12 weeks. No evidence of adrenal mineralocorticoid excess was noted (Montgomery et al 2016).…”

What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer

“…In the ARMOR3 trial, patients who progress on initial androgen deprivation therapy are screened for the presence of a resistance marker on circulating tumor cells called AR-V7-a truncation of the androgen receptor ligand binding domain at the site where both endogenous androgens and first-and second-generation androgen receptor blockers bind (106,107). The study entails randomizing patients with this resistance marker to either a conventional blocker of the androgen receptor binding domain (enzalutamide) or a drug that acts by binding at a different site in the N terminus of the androgen receptor (galeterone) (108,109). The TAXYNERGY study looks at changing the type of chemotherapy on the basis of earlyresponse markers, including circulating tumor cell number and cellular androgen receptor distribution (110).…”